Terms ending in 2029
Every in-force patent on Pharma Cinq, LLC's record whose computed term ends in 2029, whoever holds it now. Soonest term end first, then patent number.
| Patent | Title | Holder | Status | Expires | Confidence |
|---|---|---|---|---|---|
| US 9,115,072 | Compounds and Method for Reducing Uric Acid In force (reinstated) · High confidence | Pharma Cinq, LLC | In force (reinstated) | High confidence | |
| US 8,178,675 | Compounds for the Treatment of Metabolic Disorders In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 8,889,724 | Tetrazole Compounds for Reducing Uric Acid In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 8,557,531 | Detection of Circulating Endothelial Cells In force · High confidence | Pharma Cinq, LLC | In force | High confidence | |
| US 8,481,595 | Compounds for the Treatment of Metabolic Disorders In force · High confidence | Pharma Cinq, LLC | In force | High confidence |
5 of 5 patents shown. Soonest term end first, then patent number.
Updated Nov 17, 2026 · includes USPTO assignment data published Nov 16, 2026, status data published Nov 17, 2026 and grant & fee data published Nov 17, 2026 (weekly) · how we know
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.